Answers are grounded in this paper and cite their sources.
The results suggest that the two palbociclib combinations yielded significantly greater PFS than endocrine therapy in treatment-naïve and previously treated patients with advanced/metastatic breast cancer. Palbociclib plus fulvestrant was associated with significantly less toxicity than everolimus plus exemestane.
No takes yet. Share an insight, caveat, or question.
Chirila et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: